Home LiteratureArticle Details
PMID: 7745467 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.

Journal of neuro-oncology ·Vol. 22 ·No. 2 ·1994-00-00 ·Pages 153-60

Mohanam S, Sawaya RE, Yamamoto M, Bruner JM, Nicholson GL, Rao JS

Abstract

The cellular receptor for urokinase-type plasminogen activator (uPAR) in glioblastoma cell lines has been identified and found to be similar to the uPAR expressed by other tumor cell lines. Increased levels of uPAR have been found in primary malignant brain tumor tissues, especially highly malignant glioblastoma, and, to a lesser degree, in malignant astrocytomas, suggesting that this receptor might be involved in efficient activation of pro-uPA and confinement of uPA activity on the cell surface of invading brain tumors. The cell surface uPARs in gliomas could constitute an optimum environment for the generation and activity of plasmin, which is known to play a crucial role in the dissolution of the extracellular matrix during tumor cell invasion. In situ hybridization studies have shown that uPAR mRNA is expressed abundantly in tumor cells and is consistently present at the invasive edges of malignant gliomas. These results imply that uPAR is involved in plasmin-catalyzed proteolysis during glioma invasion and that interference with the uPA:uPAR interactions could constitute a novel approach for developing therapeutic strategies to counteract invasion of brain tumors.

MeSH Terms
Brain Neoplasms/enzymology,metabolism,pathology Humans Neoplasm Invasiveness Peptide Hydrolases/metabolism Receptors, Cell Surface/physiology Receptors, Urokinase Plasminogen Activator
Chemicals
PLAUR protein, human Receptors, Cell Surface Receptors, Urokinase Plasminogen Activator Peptide Hydrolases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Mohanam S
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Sawaya R E
Yamamoto M
Bruner J M
Nicholson G L
Rao J S
References (49)
49 references, click to expand
  1. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
    J Biol Chem. 1994 Mar 18;269(11):8319-23 PMID: 7907591
  2. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.
    Biochemistry. 1989 Nov 14;28(23):8951-66 PMID: 2690952
  3. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
    Cancer Res. 1991 Jul 15;51(14):3690-5 PMID: 1648443
  4. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    J Biol Chem. 1992 May 5;267(13):9129-33 PMID: 1315748
  5. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    J Cell Biol. 1991 Oct;115(1):191-9 PMID: 1918136
  6. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
    Ann N Y Acad Sci. 1992 Dec 4;667:13-31 PMID: 1339241
  7. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
    J Cell Biol. 1989 May;108(5):1987-95 PMID: 2523891
  8. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
    J Cell Biol. 1988 Jan;106(1):87-95 PMID: 3123496
  9. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.
    FEBS Lett. 1994 Feb 7;338(3):239-45 PMID: 8307187
  10. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.
    Cancer Res. 1988 Jan 15;48(2):291-6 PMID: 3121170
  11. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.
    EMBO J. 1991 Nov;10(11):3399-407 PMID: 1655420
  12. Structure and function of the urokinase receptor.
    Blood Coagul Fibrinolysis. 1993 Apr;4(2):293-303 PMID: 8388742
  13. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.
    Cancer Res. 1991 Jan 1;51(1):274-81 PMID: 1988089
  14. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
    Cell Regul. 1991 Oct;2(10 ):793-803 PMID: 1666303
  15. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.
    FEBS Lett. 1991 Aug 19;288(1-2):233-6 PMID: 1715292
  16. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.
    J Biol Chem. 1991 Apr 25;266(12):7842-7 PMID: 1850423
  17. Plasminogen activator-dependent pericellular proteolysis.
    Br J Haematol. 1991 Dec;79(4):537-43 PMID: 1663384
  18. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    J Biol Chem. 1991 Mar 15;266(8):5147-52 PMID: 1900515
  19. Plasminogen activator inhibitors: hormonally regulated serpins.
    Mol Cell Endocrinol. 1990 Jan 2;68(1):1-19 PMID: 2105900
  20. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
    J Biol Chem. 1991 Jul 5;266(19):12752-8 PMID: 1829461
  21. The role of proteolytic enzymes in cancer invasion and metastasis.
    Clin Exp Metastasis. 1992 May;10(3):145-55 PMID: 1582084
  22. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.
    J Biol Chem. 1993 Mar 15;268(8):5985-9 PMID: 8383683
  23. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    J Biol Chem. 1992 Jul 25;267(21):14543-6 PMID: 1378833
  24. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase.
    Biochem Biophys Res Commun. 1992 Jul 15;186(1):348-54 PMID: 1321608
  25. Plasminogen activator activity and molecular weight patterns in human brain tumors.
    J Neurosurg. 1988 Jan;68(1):73-9 PMID: 3335914
  26. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.
    Cell. 1991 Jan 25;64(2):327-36 PMID: 1703045
  27. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts.
    FEBS Lett. 1994 Jan 24;338(1):69-74 PMID: 8307160
  28. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
    Cancer Res. 1993 Sep 15;53(18):4143-7 PMID: 8395977
  29. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    J Cell Biol. 1991 Nov;115(4):1107-12 PMID: 1659573
  30. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
    Cancer Res. 1994 Feb 15;54(4):1105-8 PMID: 8313368
  31. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Proc Natl Acad Sci U S A. 1990 Mar;87(6):2230-4 PMID: 2138329
  32. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
    EMBO J. 1990 Feb;9(2):467-74 PMID: 1689240
  33. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
    J Cell Biol. 1990 Aug;111(2):783-92 PMID: 2166055
  34. Plasminogen activators and cancer.
    Blood Coagul Fibrinolysis. 1990 Dec;1(6):681-7 PMID: 2133247
  35. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
    Eur J Biochem. 1992 Apr 15;205(2):451-8 PMID: 1374026
  36. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.
    J Biol Chem. 1989 Feb 5;264(4):2185-8 PMID: 2521625
  37. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
    J Biol Chem. 1990 Jun 15;265(17):9904-8 PMID: 2161846
  38. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
    Blood. 1991 Jul 15;78(2):479-87 PMID: 1648983
  39. Structure of vitronectin and its biological role in haemostasis.
    Thromb Haemost. 1991 Jul 12;66(1):123-32 PMID: 1718050
  40. Plasminogen activators, tissue degradation, and cancer.
    Adv Cancer Res. 1985;44:139-266 PMID: 2930999
  41. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2.
    Am J Hum Genet. 1992 Mar;50(3):492-7 PMID: 1311495
  42. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.
    FEBS Lett. 1993 Jul 12;326(1-3):69-74 PMID: 8392005
  43. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
    J Cell Biol. 1991 Dec;115(6):1763-71 PMID: 1661735
  44. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.
    J Biol Chem. 1991 Jan 25;266(3):1926-33 PMID: 1846368
  45. Directed plasminogen activation at the surface of normal and malignant cells.
    Adv Cancer Res. 1991;57:273-328 PMID: 1950706
  46. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy.
    Cancer Metastasis Rev. 1990 Dec;9(4):333-52 PMID: 2097084
  47. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.
    J Cell Biol. 1990 Nov;111(5 Pt 1):2183-95 PMID: 1699954
  48. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
    Cancer Res. 1992 Jun 1;52(11):3043-7 PMID: 1375533
  49. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.
    J Cell Biol. 1989 Feb;108(2):693-702 PMID: 2537321
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
0167-594X
Published
1994-00-00
Pages
153-60
Language
English
Region
United States
NLM ID
8309335
Subset
IM
Grants
NCI NIH HHS · CA 44352 · United States
NCI NIH HHS · CA 56792 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]